Home blood pressure monitoring (HBPM) is increasingly being recognized as an accurate adjunct to clinic blood pressure measurement for the diagnosis and management of hypertension. We discussed the HOPE Asia Network’s recently published consensus recommendations on HBPM with lead author, Prof. Sungha Park.
Click here to view the interview video with one of the authors - Professor Sungha Park
In an effort to better understand hypertension subtypes – including morning and white-coat hypertension – in Asian patients, the HOPE Asia Network has initiated the Asia BP@Home study across 12 countries and regions. We discussed the study’s design and objectives with lead investigator, Prof. Kazuomi Kario.
Click here to view the interview video with lead investigator - Professor Kazuomi Kario
Data presented at the 13th APCH, and recently published in the Journal of Clinical Hypertension, highlighted the current challenges of hypertension management in Asia and how home blood pressure monitoring may improve cardiovascular outcomes. We discussed the paper with lead author, Prof. Yook-Chin Chia.
Results from the ASCOT-LLA study suggest that patient reports of muscle-related adverse events were more common when patients knew they were being treated with a statin. We discussed this phenomenon, known as the ‘nocebo effect’, with senior investigator, Prof. Peter Sever.
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
New drug applications approved by US FDA as of 16 - 31 May 2017 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.